Related references
Note: Only part of the references are listed.NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin
Winnie Yeo et al.
BMJ SUPPORTIVE & PALLIATIVE CARE (2022)
A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients
Winnie Yeo et al.
BREAST (2020)
Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life
Meinolf Karthaus et al.
FUTURE ONCOLOGY (2020)
Impact of adherence to antiemetic guidelines on the incidence of chemotherapy-induced nausea and vomiting and quality of life
Nibal Abunahlah et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2016)
Role of Psychosocial Variables on Chemotherapy-Induced Nausea and Vomiting and Health-Related Quality of Life among Cancer Patients: A European Study
Luigi Grassi et al.
PSYCHOTHERAPY AND PSYCHOSOMATICS (2015)
Nausea still the poor relation in antiemetic therapy? The impact on cancer patients' quality of life and psychological adjustment of nausea, vomiting and appetite loss, individually and concurrently as part of a symptom cluster
Carlo Pirri et al.
SUPPORTIVE CARE IN CANCER (2013)
The impact of chemotherapy-related nausea on patients' nutritional status, psychological distress and quality of life
Carole Farrell et al.
SUPPORTIVE CARE IN CANCER (2013)
Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study
Doranne L. Hilarius et al.
SUPPORTIVE CARE IN CANCER (2012)
Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life
P. Fernandez-Ortega et al.
SUPPORTIVE CARE IN CANCER (2012)
Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study
Carlo Pirri et al.
SUPPORTIVE CARE IN CANCER (2011)
Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population
Amin Haiderali et al.
SUPPORTIVE CARE IN CANCER (2011)
A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy
Winnie Yeo et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
How do patient expectancies, quality of life, and postchemotherapy nausea interrelate?
Ben Colagiuri et al.
CANCER (2008)
Drug therapy: Chemotherapy-induced nausea and vomiting
Paul J. Hesketh
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre
A. Molassiotis et al.
SUPPORTIVE CARE IN CANCER (2008)
Chemotherapy-induced nausea and vomiting-incidence and impact on patient quality of life at community oncology settings
Lorenzo Cohen et al.
SUPPORTIVE CARE IN CANCER (2007)
The impact of chemotherapy-induced nausea and vomiting on health-related quality of life
Enzo Ballatori et al.
SUPPORTIVE CARE IN CANCER (2007)
Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment
Brigitte Bloechl-Daum et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Chemotherapy-induced nausea and vomiting in routine practice:: a European perspective
A Glaus et al.
SUPPORTIVE CARE IN CANCER (2004)
Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall
AR Martin et al.
SUPPORTIVE CARE IN CANCER (2003)
Chemotherapy-induced nausea and vomiting: The importance of acute antiemetic control
FM Schnell
ONCOLOGIST (2003)
Share Paper
